Customised virus-like particles: Opening a new chapter for clinical precision gene therapy

Xingyu Zhu; Qingye Zhang; Xujiao Zhou; Yujia Cai; Jiaxu Hong

doi:10.1002/ctm2.70395

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (7) : e70395 DOI: 10.1002/ctm2.70395

EDITORIAL

Customised virus-like particles: Opening a new chapter for clinical precision gene therapy

Author information +

History +

PDF

Cite this article

Download citation ▾

Xingyu Zhu, Qingye Zhang, Xujiao Zhou, Yujia Cai, Jiaxu Hong. Customised virus-like particles: Opening a new chapter for clinical precision gene therapy. Clinical and Translational Medicine, 2025, 15(7): e70395 DOI:10.1002/ctm2.70395

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337(6096): 816-821.

[2]	Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. 2012; 109(39): E2579-2586.

[3]	Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339(6121): 819-823.

[4]	Khirallah J, Eimbinder M, Li Y, Xu Q. Clinical progress in genome-editing technology and in vivo delivery techniques. Trends Genet. 2023; 39(3): 208-216.

[5]	Rostami N, Gomari MM, Choupani E, et al. Exploring advanced CRISPR delivery technologies for therapeutic genome editing. Small Science. 2024: 2400192.

[6]	Wei A, Yin D, Zhai Z, et al. In vivo CRISPR gene editing in patients with herpetic stromal keratitis. Mol Ther. 2023; 31(11): 3163-3175.

[7]	Banskota S, Raguram A, Suh S, et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell. 2022; 185(2): 250-265.e16.

[8]	Ling S, Zhang X, Dai Y, et al. Customizable virus-like particles deliver CRISPR-Cas9 ribonucleoprotein for effective ocular neovascular and Huntington's disease gene therapy. Nat Nanotechnol. 2025; 20(4): 543-553.

[9]	Hamilton JR, Tsuchida CA, Nguyen DN, et al. Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Rep. 2021; 35(9): 109207.

[10]	Hamilton JR, Chen E, Perez BS, et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat Biotechnol. 2024; 42(11): 1684-1692.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.